Efficacy of Botulinum Toxin in Treating Asian Indian Patients with Masseter Hypertrophy: A 4-Year Follow-Up Study.
Adult
Asian People
Beauty
Botulinum Toxins, Type A
/ administration & dosage
Cosmetic Techniques
Drug Administration Schedule
Face
/ anatomy & histology
Female
Follow-Up Studies
Humans
Hypertrophy
/ drug therapy
India
Injections, Intramuscular
Male
Masseter Muscle
/ abnormalities
Middle Aged
Neuromuscular Agents
/ administration & dosage
Photography
Prospective Studies
Treatment Outcome
Ultrasonography
Young Adult
Journal
Plastic and reconstructive surgery
ISSN: 1529-4242
Titre abrégé: Plast Reconstr Surg
Pays: United States
ID NLM: 1306050
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
18
1
2020
Statut:
ppublish
Résumé
Asian Indians usually have wide lower faces because of masseter hypertrophy. The authors evaluated the efficacy of botulinum toxin type A in long-term management of bilateral masseter hypertrophy in Asian Indian patients. Fifty patients were enrolled in the study and injected with 30 U of botulinum toxin type A to each side of the face, at baseline. Based on masseter muscle thickness and response to the injections, 25 patients underwent a second injection session at week 12, and the other 25 patients underwent additional third sessions, at week 24 after the first injection, respectively. Standardized photography and ultrasonography were performed to assess facial contour and masseter muscle thickness at baseline and at 1-, 2-, 3-, and 4-year follow-ups. A p value < 0.05 was considered statistically significant. The authors observed 12 percent (p < 0.0001) average masseter muscle size reduction at week 12. The maximum reduction (26.6 percent; p < 0.0001) was observed at week 24 for the patients who received two injections and maintained an average 24.43 percent (p < 0.0001) reduction until follow-up at year 4. Patients who received three injections exhibited very high reduction (42.52 percent; p < 0.0001) of masseter volume at week 36 and maintained an average 40.64 percent (p < 0.0001) reduced volume until year 4. Botulinum toxin type A treatment is effective for long-term management of bilateral masseter hypertrophy. Doses repeated at 12-week intervals accentuate masseter volume reduction and also help maintain reduced masseter volume for 4-year follow-up, with satisfactory facial contour.
Sections du résumé
BACKGROUND
Asian Indians usually have wide lower faces because of masseter hypertrophy. The authors evaluated the efficacy of botulinum toxin type A in long-term management of bilateral masseter hypertrophy in Asian Indian patients.
METHODS
Fifty patients were enrolled in the study and injected with 30 U of botulinum toxin type A to each side of the face, at baseline. Based on masseter muscle thickness and response to the injections, 25 patients underwent a second injection session at week 12, and the other 25 patients underwent additional third sessions, at week 24 after the first injection, respectively. Standardized photography and ultrasonography were performed to assess facial contour and masseter muscle thickness at baseline and at 1-, 2-, 3-, and 4-year follow-ups. A p value < 0.05 was considered statistically significant.
RESULTS
The authors observed 12 percent (p < 0.0001) average masseter muscle size reduction at week 12. The maximum reduction (26.6 percent; p < 0.0001) was observed at week 24 for the patients who received two injections and maintained an average 24.43 percent (p < 0.0001) reduction until follow-up at year 4. Patients who received three injections exhibited very high reduction (42.52 percent; p < 0.0001) of masseter volume at week 36 and maintained an average 40.64 percent (p < 0.0001) reduced volume until year 4.
CONCLUSIONS
Botulinum toxin type A treatment is effective for long-term management of bilateral masseter hypertrophy. Doses repeated at 12-week intervals accentuate masseter volume reduction and also help maintain reduced masseter volume for 4-year follow-up, with satisfactory facial contour.
Identifiants
pubmed: 31461011
doi: 10.1097/PRS.0000000000005944
pii: 00006534-201909000-00016
doi:
Substances chimiques
Neuromuscular Agents
0
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
390e-396eCommentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Chang CS, Bergeron L, Yu CC, Chen PK, Chen YR. Mandible changes evaluated by computed tomography following botulinum toxin A injections in square-faced patients. Aesthetic Plast Surg. 2011;35:452–455.
Ahn KY, Kim ST. The change of maximum bite force after botulinum toxin type a injection for treating masseteric hypertrophy. Plast Reconstr Surg. 2007;120:1662–1666.
Rispoli DZ, Camargo PM, Pires JL Jr, Fonseca VR, Mandelli KK, Pereira MAC. Benign masseter muscle hypertrophy. Braz J Otorhinolaryngol. 2008;74:790–793.
von Lindern JJ, Niederhagen B, Appel T, Bergé S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: An alternative treatment. Plast Reconstr Surg. 2001;107:327–332.
Ahn J, Horn C, Blitzer A. Botulinum toxin for masseter reduction in Asian patients. Arch Facial Plast Surg. 2004;6:188–191.
Wanitphakdeedecha R, Ungaksornpairote C, Kaewkes A, Sathaworawong A, Lektrakul N, Manuskiatti W. The efficacy of two formulations of botulinum toxin type A for masseter reduction: A split-face comparison study. J Dermatolog Treat. 2017;28:443–446.
Nayyar P, Kumar P, Nayyar PV, Singh A. BOTOX: Broadening the horizon of dentistry. J Clin Diagn Res. 2014;8:ZE25–ZE29.
Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA. Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy. An Bras Dermatol. 2014;89:878–884.
Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg. 2010;125:1693–1705.
Kapoor KM, Chatrath V, Anand C, et al. Consensus recommendations for treatment strategies in Indians using botulinum toxin and hyaluronic acid fillers. Plast Reconstr Surg Glob Open 2017;5:e1574.
Sharad J. Contouring of lower face with injection of botulinum toxin into the masseter muscle. J Appl Aesthet. 2015;15:1.
Bhattacharjee K, Singh M, Bhattacharjee H. Extended effect after a single dose of type A botulinum toxin for asymmetric masseter muscle hypertrophy. Indian J Plast Surg. 2015;48:196–199.
Shome D, Nair AG, Kapoor R, Jain V. Botulinum toxin A: Is it really that fragile a molecule? Dermatol Surg. 2010;36(Suppl 4):2106–2110.
Kapoor R, Shome D, Jain V, Dikshit R. Facial rejuvenation after intradermal botulinum toxin: Is it really the botulinum toxin or is it the pricks? Dermatol Surg. 2010;36(Suppl 4):2098–2105.
Xie Y, Zhou J, Li H, Cheng C, Herrler T, Li Q. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment. Plast Reconstr Surg. 2014;134:209e–218e.
Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003;29:484–489.
Yu CC, Chen PK, Chen YR. Botulinum toxin a for lower facial contouring: A prospective study. Aesthetic Plast Surg. 2007;31:445–451; discussion 452–453.
Fedorowicz Z, van Zuuren EJ, Schoones J. Botulinum toxin for masseter hypertrophy. Cochrane Database Syst Rev 2013;9:CD007510.
Lee HJ, Kim SJ, Lee KJ, Yu HS, Baik HS. Repeated injections of botulinum toxin into the masseter muscle induce bony changes in human adults: A longitudinal study. Korean J Orthod. 2017;47:222–228.
Moon YM, Kim MK, Kim SG, Kim TW. Apoptotic action of botulinum toxin on masseter muscle in rats: Early and late changes in the expression of molecular markers. Springerplus 2016;5:991.
Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of muscle fiber response of dose-related diffusion and after therapeutic botulinum A toxin injections. Mov Disord. 1994;1:31–39.
Grünheid T, Langenbach GE, Korfage JA, Zentner A, van Eijden TM. The adaptive response of jaw muscles to varying functional demands. Eur J Orthod. 2009;31:596–612.